Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
US FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
The US Food and Drug Administration's boxed warnings on the labels of Rinvoq , Xeljanz and Olumiant flags the risk of…
Vaccine makers could make Omicron-specific booster, says Fauci
The US government is working with Moderna, Pfizer and J&J on multiple contingency plans, infectious disease expert Anthony…
Covishield current monthly production capacity 250-275 million doses, Covaxin 50-60 million doses,…
Both companies have achieved close to 90 per cent of present production capacity, Bharati Pravin Pawar, Minister of State for…
Eris Lifesciences announces Joint Venture with MJ Biopharm to offer insulin in India
The 70:30 Joint Venture will primarily engage in marketing and distribution of human and analogue insulin including Aspart,…
FDA expands authorisation of two monoclonal antibodies for treatment and post-exposure prevention…
Amlanivimab and Etesevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2,…
Pharma industry reports 53 deals worth $9.6 billion in November 2021: GlobalData
The industry reported 105 venture capital (VC) deals worth $4.2 billion in November 2021, compared to the last 12-month average…
SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody…
Under the agreement, Biomodifying is eligible for an upfront payment, milestone payments on pre-specified clinical, regulatory,…
Coping and thriving through COVID-19
As 2021 is about to end, a few stakeholders from the pharma industry share some key lessons learnt in the past year
Morepen gets US FDA approval for Fexofinadine
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
10th Indian Pharma Expo to be held from 10-11 December in Delhi
IPE offers opportunities for the participating companies to meet, showcase and promote their products and services to visitors…